H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Biomea Fusion to $50 from $37 and keeps a Buy rating on the shares after the company presented new clinical data from the Phase 2 COVALENT-111 trial evaluating the covalent menin inhibitor, BMF-219, as a potential treatment for patients with type 2 diabetes. The analyst says BMF-219 stands out with initial off-treatment period results and that dose escalation progressing as planned.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
- Biomea Soars on Promising Phase 2 Data in Type 2 Diabetes
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- Biomea Fusion price target raised to $60 from $50 at Barclays
- Citi ups Biomea Fusion target to $90, elevates to ‘Top Pick’